US/UK/Canada

Share

Contacts

  • Leo Holmgren

    CEO


    +46 70 049 18 42

    • Links

    Quotes

    Completing the toxicology program with these positive results is a major milestone for Pharmability. The data show that our drug candidate is well tolerated even at high exposure levels and, importantly, that systemic exposure is minimal following cutaneous administration. This strengthens the safety profile of cutaneous TIR-C treatment as we prepare for the Phase Ib study in atopic dermatitis.
    Leo Holmgren, CEO, Pharmability
    We are very pleased to welcome Agneta to Pharmability. Her extensive experience in clinical project management and early-phase development strengthens our capacity as we advance TIR-C into its next stage of development and continue building a strong and experienced project team.
    Leo Holmgren, CEO, Pharmability
    Pharmability marks a new chapter for the company. The name captures our ambition to translate immunological research into new therapies and create value for patients as we enter the next phase.
    Leo Holmgren, CEO, Pharmability
    This publication provides important mechanistic insight into how TIR-01 interacts with early myeloid differentiation and promotes the development of tolerogenic dendritic cells. The data strengthen the scientific rationale behind our immunomodulatory strategy and support the continued advancement of our development program toward clinical studies.
    Leo Holmgren, CEO, TIRmed Pharma
    The collaboration with Bachem is an important milestone in our efforts to advance our candidate drug to the clinic. Through this collaboration, we gain access to world-leading manufacturing expertise and strengthen the foundation for offering patients a more durable treatment option
    Leo Holmgren, CEO, TIRmed Pharma
    The expanded partnership with Zelmic marks a milestone in the clinical development of TIR-C. Zelmic’s deep expertise in topical formulation development strengthens the foundation for our clinical program and supports our mission to improve treatment outcomes for patients with atopic dermatitis worldwide.
    Leo Holmgren, CEO, TIRmed Pharma
    These are the final safety studies before entering the clinic – a critical milestone in our development program. ERBC’s experience with this type of study makes them a valuable partner, and with their support, we are confident in generating the data needed to move into Phase I next year.
    Leo Holmgren, CEO, TIRmed Pharma
    We are very pleased to welcome Peder Walberg and Christian Krog-Jensen to the board. Their complementary expertise in clinical development, strategic planning, and financing will be essential as we bring TIR-C into the clinic and position the company for long-term success
    Leo Holmgren, CEO, TIRmed Pharma
    Bringing TIR-C into the clinic is a major milestone for us – and it demands the right team. Elisabeth brings not only extensive experience, but also the strategic mindset we need at this stage. Her contributions will be essential as we move through the regulatory process and prepare for clinical execution.
    Leo Holmgren, CEO of TIRmed Pharma.
    This capital injection enables us to take the decisive step into clinical development and move closer to a future where patients have access to more durable and effective treatment. The strong support from Sciety and their investor network gives us both the momentum and the means to accelerate our development.
    Leo Holmgren, CEO, TIRmed Pharma
    Pick a time period -
    Tags ( Active)
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media